Literature DB >> 12431757

Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities.

Derek LeRoith1.   

Abstract

Defects in insulin action and insulin secretion are both present in type 2 diabetes, and both are believed to be genetically predetermined. In the absence of a defect in beta-cell function, individuals can compensate indefinitely for insulin resistance with appropriate hyperinsulinemia, as observed even in obese populations such as the Pima Indians of Arizona. However, loss of beta-cell function leads eventually to the postprandial and fasting hyperglycemia that characterizes type 2 diabetes. This progression occurs despite initially effective antidiabetic therapies, a situation clearly demonstrated by the United Kingdom Prospective Diabetes Study (UKPDS). External factors (access to high-calorie foods, lack of exercise, weight gain), the increased insulin requirements imposed by insulin resistance, and toxicities from hyperglycemia and elevated free fatty acids may all contribute to beta-cell deterioration. Free fatty acids, resistin, and tumor necrosis factor (TNF)-alpha potentially worsen the insulin resistance. beta-Cell dysfunction resulting from glucose toxicity and lipotoxicity is potentially reversible with restoration of metabolic control. Therefore, attention to these toxicities may delay the deterioration of beta-cell function and suggest new approaches to the management of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431757     DOI: 10.1016/s0002-9343(02)01276-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  43 in total

1.  Modulation of neuronal pentraxin 1 expression in rat pancreatic β-cells submitted to chronic glucotoxic stress.

Authors:  Domitille Schvartz; Yohann Couté; Yannick Brunner; Claes B Wollheim; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2012-03-16       Impact factor: 5.911

Review 2.  Glucose-sensing mechanisms in pancreatic beta-cells.

Authors:  Patrick E MacDonald; Jamie W Joseph; Patrik Rorsman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

Review 3.  Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy.

Authors:  Louis Kuritzky
Journal:  MedGenMed       Date:  2006-11-15

Review 4.  The good, the bad, and the ugly facets of insulin resistance.

Authors:  K V S Hari Kumar
Journal:  Med J Armed Forces India       Date:  2020-01-06

Review 5.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 6.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma.

Authors:  Feliciano Priego-Capote; Alexander Scherl; Markus Müller; Patrice Waridel; Frédérique Lisacek; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2009-11-06       Impact factor: 5.911

8.  Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

Authors:  Ildiko Lingvay; Jaime L Legendre; Polina F Kaloyanova; Song Zhang; Beverley Adams-Huet; Philip Raskin
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

9.  Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Jan A Ehses; Zoltan Mathe; Domenico Bosco; Thierry Berney; Jean-Michel Dayer; Manfred Reinecke; Philippe A Halban; Marc Y Donath
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

Review 10.  Modulation of insulin action.

Authors:  L Pirola; A M Johnston; E Van Obberghen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.